63 results on '"Parra-Cordero M"'
Search Results
2. EP15.02: Perinatal outcomes of fetuses with nuchal translucency > 99th percentile at 11–14 weeks' scan and normal karyotype: a single Chilean institutional study
3. EP38.06: Variability in the diagnosis and management of fetal growth restriction across Latin America and the Caribbean
4. VP34.01: Customised Doppler standards for the definition of late fetal growth restriction
5. OP03.05: Mental wellbeing among pregnant and postpartum women during the COVID‐19 pandemic: a large international survey
6. VP37.10: Impact of maternal physiological characteristics on UA and MCA fetal Doppler near term within a randomised controlled trial
7. Quality assessment of fetal middle cerebral and umbilical artery Doppler images using an objective scale within an international randomized controlled trial
8. EP12.07: Prenatal diagnosis of corrected transposition of great arteries: 13‐case series and systematic review of literature
9. P19.12: Is first trimester saliva progesterone level associated with spontaneous preterm delivery?
10. P20.06: Agenesis of the ductus venosus: prenatal diagnosis, perinatal outcomes and systematic review of literature
11. P17.02: Prenatal diagnosis of neuroblastoma: a report of seven cases and systematic review of literature
12. EP04.15: Reference range of fetal nasal bone and its role for aneuploidy screening 11+0–13+6 weeks in a Chilean population
13. EP16.21: Fetal diagnosis of anomalous renal vein shunt into azygos vein
14. EP20.21: Combined predictive model of birthweight at diagnosis of early and late onset pre‐eclampsia
15. EP20.19: Role of cerebroplacental ratio in normal growing fetus for the detection of abnormal perinatal outcomes
16. EP04.02: Ultrasound reference ranges for fetal prenasal thickness and its role as screening test for chromosomal abnormalities at 16–25 weeks of gestation
17. P21.01: Perinatal outcomes of pregnancies conceived by assisted reproductive technologies in an 11+0 - 13+6 weeks screening program
18. OP13.11: Placental mesenchymal dysplasia: four cases
19. P16.01: Maternal plasma nerve growth factor at 11 to 13 weeks as a novel angiogenic marker of pre‐eclampsia
20. P16.07: Characterisation of immune patterns in pregnancies defined as high‐ or low‐risk according to first trimester uterine artery Doppler
21. OP12.04: Lymphocytes and cytokines pattern as potential markers for screening of pre‐eclampsia and fetal growth restriction during the first trimester of pregnancy
22. P16.03: Role of mean blood pressure as screening test for small‐for‐gestational age without pre‐eclampsia during the first trimester of pregnancy
23. P14.07: Twin pregnancy: screening test for spontaneous preterm delivery and pre‐eclampsia during the first trimester of pregnancy
24. OP12.07: Prediction of pre‐eclampsia by maternal characteristic and biophysical markers during the first trimester of pregnancy
25. EP04.07: Case report: double aortic arch – two cases
26. P30.09: Case report: prenatal diagnosis of intracranial aneurysm
27. P13.10: Outcomes in fetuses with agenesis of ductus venosus
28. P06.11: Case report: fetal cardiac aneurysm
29. OC08.05: A randomised trial of arginine supplementation to prevent pre‐eclampsia
30. P06.10: Fetal cardiac tumours, diagnosis and prognosis
31. OP12.04: Are first or second trimester uterine artery Doppler assessment predictors of adverse outcome in pregnancies with systemic lupus erythematosus?
32. P13.13: First trimester predictive model of small‐for‐gestational age newborn without pre‐eclampsia
33. OP02.02: First-trimester maternal biochemical markers as predictors of spontaneous early preterm delivery
34. P19.02: Twin pregnancy: screening test for spontaneous preterm delivery and pre‐eclampsia during the first trimester of pregnancy
35. OP18.04: Role or first trimester ultrasound in the prediction of stillbirth over 20 weeks
36. OP12.02: First and second trimester combined screening for pre‐eclampsia
37. Is there a role for cervical assessment and uterine artery Doppler in the first trimester of pregnancy as a screening test for spontaneous preterm delivery?
38. Prediction of early and late pre‐eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy
39. OC05.04: Adverse pregnancy outcome in foetuses with increased nuchal translucency during the first trimester of pregnancy in a Chilean population
40. OP08.08: Screening of spontaneous preterm delivery by obstetric history and second trimester ultrasound in an unselected Chilean population
41. OC09.04: Is there any role for first trimester cervical assessment and uterine artery Doppler as screening test for spontaneous early preterm delivery?
42. OP09.01: Thyroid-stimulating hormone at 11 + 0 to 13 + 6 weeks of gestation and its role as screening for pre-eclampsia and small gestational age newborns
43. OC23.04: A risk model for pre-eclampsia based on maternal characteristics and uterine artery Doppler during the first trimester of pregnancy
44. OP01.03: Fetal PR interval in pregnant women with positive anti SSA/Ro and anti SSA/La antibodies, and risk of developing fetal heart block
45. OP16.07: Uterine artery Doppler during the second trimester of gestation in the screening for thrombophilic disorders
46. OP37.01: First trimester maternal serum PP13 as screening test for preeclampsia and small gestational age
47. OC17.01: Risk assessment for early spontaneous preterm delivery combining markers from the first and second trimester of pregnancy
48. OC15.02: Twin pregnancy: screening test for spontaneous preterm delivery and preeclampsia during the second trimester of pregnancy
49. P04.01: Value of including other ultrasound markers different to nuchal translucency to detect fetal aneuploidy at 11 + 0 to 13 + 6 weeks
50. OP01.06: Cardiovascular parameters in the prediction of mortality in early-onset intrauterine growth restriction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.